FDA Proposes “Sinusitis” Exclusion From OTC Nasal Decongestant Monograph
This article was originally published in The Tan Sheet
Executive Summary
FDA is seeking to amend the OTC nasal decongestant monograph by removing the indications that reference "sinusitis," the agency announced in a proposed rule slated for publication in the Aug. 2 Federal Register